GlassScriptPhysician profile
Richard Rubinowicz
NPI 1033150404
$4,385.49
in general payments reported to CMS, 2019-2025
36 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $439 · 2021: $562 · 2022: $605 · 2023: $587 · 2024: $593 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $492.02 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $437.23 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Neurocrine Biosciences, INC. | $388.56 | 2019-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $311.61 | 2019-2023 | |
| Pfizer INC. | $284.08 | 2021-2025 | |
| Abbvie INC. | $243.89 | 2021-2024 | Qulipta, Ubrelvy |
| Biogen, INC. | $238.94 | 2019-2023 | Vumerity |
| Sk Life Science, INC. | $229.56 | 2020-2025 | |
| Amgen INC. | $218.88 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $215.62 | 2019-2022 | |
| Eisai INC. | $133.08 | 2019-2025 | |
| Emd Serono, INC. | $125.63 | 2019-2025 | Mavenclad |
| Ucb, INC. | $120.50 | 2019-2025 | Rystiggo, Fintepla |
| Tg Therapeutics, INC. | $102.21 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $97.30 | 2019-2025 | Crexont |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rubinowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.